IMV Inc is a clinical-stage immuno-oncology company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

Note: This is not a U.S. company, but they cross-list their shares on a U.S. stock exchange - see the related symbol CT:IMV.

$1.49  +0.11 (7.97%)
As of 12/02/2021 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  10/09/2009
Outstanding shares:  82,142,629
Average volume:  765,336
Market cap:   $113,356,828
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      40-F
CUSIP:    44974L103
Valuation   (See tab for details)
PE ratio:   -12.75
PB ratio:   3.73
PS ratio:   0.00
Return on equity:   -102.32%
Net income %:   -30,090,604.47%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy